Active	Status	Sponsor type	Region	Phase	Filter
12 Active 17 Inactive 29 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hochster, Howard S
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers	Active, not recruiting	2/3	150	US	CTX-009, Paclitaxel	Compass Therapeutics	Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer	07/25	12/25
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease	Recruiting	2/3	1912	Canada, US	Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month	NRG Oncology, Natera, Inc., National Cancer Institute (NCI)	Stage III Colon Cancer	03/29	03/30
QUIC, NCT06048133: Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers	Recruiting	2	39	US	Gemcitabine, Cisplatin, Zimberelimab, AB122, Quemliclustat, AB680	Nataliya Uboha, Arcus Biosciences, Inc., Gilead Sciences, University of Wisconsin, Madison	Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer	01/25	07/25
NCT05167409: A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer	Active, not recruiting	2	48	US	Evorpacept (ALX148), evorpacept, Cetuximab, Erbitux, Pembrolizumab, Keytruda	University of Colorado, Denver, ALX Oncology Inc., Merck Sharp & Dohme LLC, Eli Lilly and Company, Criterium, Inc., Academic GI Cancer Consortium (AGICC)	Microsatellite Stable Metastatic Colorectal Cancer	12/25	03/26
The AB7 Trial, NCT04829383: A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma	Active, not recruiting	2	50	US	Atezolizumab, Tecentriq, Bevacizumab, Avastin	Howard S Hochster, Genentech, Inc., Rutgers Cancer Institute of New Jersey	Unresectable Hepatocellular Carcinoma	10/24	10/25
NCT04169347: FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer	Active, not recruiting	2	27	US	Oxaliplatin, Irinotecan, Leucovorin, Panitumumab	Criterium, Inc., Amgen	Colorectal Cancer Metastatic	12/24	01/25